MA27073A1 - Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur de l'echangeur du sodium-hydrogene - Google Patents

Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur de l'echangeur du sodium-hydrogene

Info

Publication number
MA27073A1
MA27073A1 MA27610A MA27610A MA27073A1 MA 27073 A1 MA27073 A1 MA 27073A1 MA 27610 A MA27610 A MA 27610A MA 27610 A MA27610 A MA 27610A MA 27073 A1 MA27073 A1 MA 27073A1
Authority
MA
Morocco
Prior art keywords
adenosine
agonist
sodium
pharmaceutical composition
composition consisting
Prior art date
Application number
MA27610A
Other languages
English (en)
Inventor
James M Downey
Umesh Shukla
Zhelong Xu
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203596A external-priority patent/GB0203596D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MA27073A1 publication Critical patent/MA27073A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA27610A 2001-11-02 2004-04-06 Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur de l'echangeur du sodium-hydrogene MA27073A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33631501P 2001-11-02 2001-11-02
GB0203596A GB0203596D0 (en) 2002-02-15 2002-02-15 Pharmaceutical composition comprising of adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor

Publications (1)

Publication Number Publication Date
MA27073A1 true MA27073A1 (fr) 2004-12-20

Family

ID=26246972

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27610A MA27073A1 (fr) 2001-11-02 2004-04-06 Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur de l'echangeur du sodium-hydrogene

Country Status (16)

Country Link
US (1) US20040248928A1 (fr)
EP (1) EP1443916A1 (fr)
JP (1) JP2005511590A (fr)
KR (1) KR20050042225A (fr)
CN (1) CN1585634A (fr)
BR (1) BR0213820A (fr)
CA (1) CA2465364A1 (fr)
HR (1) HRP20040385A2 (fr)
HU (1) HUP0401853A2 (fr)
IL (1) IL161676A0 (fr)
MA (1) MA27073A1 (fr)
MX (1) MXPA04003124A (fr)
NO (1) NO20042142L (fr)
PL (1) PL369074A1 (fr)
RU (1) RU2004116686A (fr)
WO (1) WO2003039528A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP4664797B2 (ja) * 2005-10-13 2011-04-06 ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー Mri装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056729B1 (fr) * 1998-02-27 2004-12-29 Pfizer Products Inc. Derives de la n- (a cycle di ou triaza diinsature substitue) carbonyle] guanidine utilises pour le traitement de l'ischemie
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia

Also Published As

Publication number Publication date
JP2005511590A (ja) 2005-04-28
CN1585634A (zh) 2005-02-23
IL161676A0 (en) 2004-09-27
US20040248928A1 (en) 2004-12-09
RU2004116686A (ru) 2005-03-27
HUP0401853A2 (hu) 2004-12-28
MXPA04003124A (es) 2004-11-29
NO20042142L (no) 2004-05-25
BR0213820A (pt) 2004-08-31
KR20050042225A (ko) 2005-05-06
EP1443916A1 (fr) 2004-08-11
PL369074A1 (en) 2005-04-18
WO2003039528A1 (fr) 2003-05-15
HRP20040385A2 (en) 2005-06-30
CA2465364A1 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
FR12C0012I2 (fr) Combinaisons d'herbicides et de phytoprotecteurs
CY2008010I2 (el) Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες
DE69836525D1 (de) Betätigungsvorrichtung eines Spielgeräts
DE10196857T1 (de) Auffinden und Auswahl eines Zugriffspunkts
IT1313611B1 (it) Solfonilossime per fotoresist linea-1 di elevata sensibilita' edelevato spessore del resist
DE69623821D1 (de) Tragbarer fertilitätstester
NO983926D0 (no) Farmasöytisk kombinasjonspreparat av en inhibitor av natrium-hydrogen-veksler og et legemiddel for behandling av hjertekretslöpsykdommer
DE69830144D1 (de) Verteilter datenbankzugriff durch virtuellen umgebungsbrowser
DE69817436D1 (de) Füllvorrichtung eines Narkosemittelverdunsters
ITBO20000517A0 (it) Metodo ed unita' di applicazione di etichette
MA27073A1 (fr) Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur de l'echangeur du sodium-hydrogene
DE60116604D1 (de) Hintergrundkalibrierung eines a/d-umsetzers
LU91038B1 (fr) Inhibiteur d'absorption de monoamines
FR2848454B1 (fr) Composition pharmaceutique comprenant une association de calcitriol et d'un corticosteroide
MA26897A1 (fr) Inhibiteur de l'echangeur sodium-hydrogene de type i (nhe-1)
FR2785148B1 (fr) Nouvelles compositions herbicide a base de glyphosate et d'isoxazoles
IT1319009B1 (it) Procedimento e dipositivo per l'analisi degli errori di circuitilogici digitali
PL351865A1 (en) Application of a combination of the 1(nhe-1) type sodium-hydrogen exchanger inhibitor and some other compound in production of a drugs as well as pharmacological agent and set
FR2814368B1 (fr) Preparation pharmaceutique a base d'oxans
FR2822097B1 (fr) Robot d'inspection et d'intervention
FR2825423B1 (fr) Dispositif deviateur d'explosion
KR960023054U (ko) 타격장치의 타격수 측정장치
DK1408943T3 (da) Lægemiddelformulering indeholdende en LTB4 antagonist og et befugtningsmiddel
IT238256Y1 (it) Attrezzo per l'allenamento di allievi giocatori e di giocatori dicalcio
FR2808363B1 (fr) Dispositif de securisation d'acces perfectionne